$CAPR News

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November

What's Going On With Capricor Therapeutics Stock Monday?

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima

CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan

Capricor Therapeutics Stock Surges: What's Going On?

Why Did CAPR Stock Jump 20% After-Hours Today?

Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

Could New Long-Term Data Support Capricor’s Duchenne Therapy?

Capricor: Downgrade To Hold On Deramiocel PDUFA Extension And DMD Change

Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

Capricor Therapeutics shares rise 2.5% following August FDA update

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision